PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines

About this update from Pharmather Holdings Ltd

MEDBOTX™ represents the evolution into a broader point-of-care manufacturing platform designed for personalized medicines, peptides and advanced dose formatsPotential U.S. peptide reclassification and possible inclusion of select peptides on the Section 503A Bulks List could create a timely opportunity for MEDBOTX™ in compounding pharmacies, hospitals and personalized medicine settingsToronto, Ontario--(Newsfile Corp. - May 27, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a pharmatech company focused on enabling personalized medicine through robotic 3D printing, today announced that it is strategically evolving its platform focus from PatchPrint™ 3D printer to MEDBOTX™, the Company's robotic 3D printing platform designed for personalized medicines, peptides and advanced pharmaceutical dose formats.Figure 1. Prototype of MEDBOTX™ robotic 3D printing platformTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/11479/299010_15df9fbe7496ea96_001full.jpgPharmaTher believes MEDBOTX™ represents the next stage of the Company's growth and the evolution of its work in pharmaceutical R&D, microneedle patches, and 3D printing. By expanding beyond a single-dose format such as microneedle patches, MEDBOTX™ gives PharmaTher a broader and more scalable platform for personalized, patient-specific and small-batch pharmaceutical manufacturing. The Company expects MEDBOTX™ to become the central technology platform for its product development and sales, partnerships, and strategy in personalized medicines."MEDBOTX™ represents the next stage of PharmaTher's work in pharmaceutical drug development and manufacturing," said Fabio Chianelli, Chief Executive Officer of PharmaTher. "We believe our MEDBOTX™ platform provides a focused path to participate in the growing demand for personalized medicines, particularly peptides, where flexible, small-batch and point-of-care manufacturing may become increasingly important as the U.S. evaluates potential regulatory pathways for certain peptide compounds and specialty pharmaceuticals."MEDBOTX™ is designed as a point-of-care and small-batch manufacturing platform that may support personalized dose forms, including polypills, tablets, oral films, gels, suppositories, chews, patches, osmotic-pump formats, and other advanced drug delivery formats. Ph...

View stock analysis, news, and events for Pharmather Holdings Ltd